ReviewFrontiers in immunology2022
HP-NAP of
Review in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Potential pathogenesis ofFuture science OA · 2026Article
- Helicobacter pylori Outer Membrane Vesicles Engage TLR2 Through NapA to Promote Epithelial Association and Inflammatory Signalling.Journal of extracellular vesicles · 2026Article
- Navigating the gastric frontier of mucosal immunity againstFrontiers in immunology · 2026Review
- Enhancement of Gastric Mucosal Defense by Phytomedicine in the Context ofBiologics : targets & therapy · 2026Review
- In silico evaluation of the anti Helicobacter pylori activity of selected bioactive compounds from Aloe vera.Scientific reports · 2025Article
- Developing a potent vaccine againstExpert reviews in molecular medicine · 2024Review
- Unveiling the gastric microbiota: implications for gastric carcinogenesis, immune responses, and clinical prospects.Journal of experimental & clinical cancer research : CR · 2024Review
- An intranasal influenza virus vector vaccine protects againstJournal of virology · 2024Article
- Recombinant L. lactis vaccine LL-plSAM-WAE targeting four virulence factors provides mucosal immunity against H. pylori infection.Microbial cell factories · 2024Article
- Effects and mechanisms ofFrontiers in immunology · 2024Review
- Pivotal role ofFrontiers in medicine · 2024Review
- Design of aFrontiers in immunology · 2024Article
- The Interplay betweenInternational journal of molecular sciences · 2023Review
- Reactive Oxygen Species andAntioxidants (Basel, Switzerland) · 2023Review
- Immune response modulation in inflammatory bowel diseases byWorld journal of gastroenterology · 2023Review
- Clinical value of serum pepsinogen in the diagnosis and treatment of gastric diseases.World journal of gastrointestinal oncology · 2023Review
- Mitochondrial Function in Health and Disease: Responses to Helicobacter pylori Metabolism and Impact in Gastric Cancer Development.Current topics in microbiology and immunology · 2023Article
- The Role ofInternational journal of molecular sciences · 2022Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The miniferritin HP-NAP of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.